We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

529 hedge funds and large institutions have $17.9B invested in Abiomed Inc in 2018 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 202 increasing their positions, 184 reducing their positions, and 63 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 71 | Existing positions closed: 63

12% more capital invested

Capital invested by funds: $16B → $17.9B (+$1.93B)

10% more repeat investments, than reductions

Existing positions increased: 202 | Existing positions reduced: 184

0% more funds holding

Funds holding: 527529 (+2)

5% less funds holding in top 10

Funds holding in top 10: 2120 (-1)

41% less call options, than puts

Call options by funds: $251M | Put options by funds: $424M

Holders
529
Holders Change
+2
Holders Change %
+0.38%
% of All Funds
12.09%
Holding in Top 10
20
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-4.76%
% of All Funds
0.46%
New
71
Increased
202
Reduced
184
Closed
63
Calls
$251M
Puts
$424M
Net Calls
-$173M
Net Calls Change
-$128M
Name Holding Trade Value Shares
Change
Change in
Stake
IBT
201
International Biotechnology Trust
United Kingdom
$4.55M
TPSF
202
Texas Permanent School Fund
Texas
$4.53M -$557K -1,413 -12%
SB
203
Suntrust Banks
Georgia
$4.5M +$2.16M +5,490 +121%
Comerica Bank
204
Comerica Bank
Texas
$4.5M -$850K -2,156 -15%
Cambridge Investment Research Advisors
205
Cambridge Investment Research Advisors
Iowa
$4.4M +$253K +642 +7%
Mitsubishi UFJ Asset Management
206
Mitsubishi UFJ Asset Management
Japan
$4.23M +$1.21M +3,067 +48%
AAF
207
Andra AP-fonden
Sweden
$4.18M +$512K +1,300 +16%
DBG
208
De Burlo Group
Massachusetts
$4.18M -$13.2M -33,600 -78%
Zurich Cantonal Bank
209
Zurich Cantonal Bank
Switzerland
$4M -$62.3K -158 -2%
SLAM
210
Swiss Life Asset Management
$4M +$1.96M +4,962 +126%
Acadian Asset Management
211
Acadian Asset Management
Massachusetts
$3.98M -$18.3M -46,400 -84%
FIM
212
Freedom Investment Management
Connecticut
$3.88M +$463K +1,175 +14%
MLICM
213
Metropolitan Life Insurance Company (MetLife)
New York
$3.88M +$61.5K +156 +2%
NIPH
214
NN Investment Partners Holdings
Netherlands
$3.84M
Public Employees Retirement Association of Colorado
215
Public Employees Retirement Association of Colorado
Colorado
$3.79M +$3.94K +10 +0.1%
RJFSA
216
Raymond James Financial Services Advisors
Florida
$3.74M -$2.07M -5,252 -39%
AL
217
AJO LP
Pennsylvania
$3.67M +$3.22M +8,161 New
Brown Advisory
218
Brown Advisory
Maryland
$3.63M +$9.07K +23 +0.3%
AG
219
Advisor Group
Arizona
$3.62M +$1.23M +3,113 +63%
YIA
220
YHB Investment Advisors
Connecticut
$3.58M -$276K -700 -8%
URS
221
Utah Retirement Systems
Utah
$3.55M
NMIMC
222
Northwestern Mutual Investment Management Company
Wisconsin
$3.53M -$94.2K -239 -3%
XK
223
Xact Kapitalforvaltning
Sweden
$3.47M -$228K -578 -7%
Credit Agricole
224
Credit Agricole
France
$3.43M -$69.8K -177 -2%
EAMA
225
EFG Asset Management (Americas)
Florida
$3.4M +$1.34M +3,400 +82%

ABMD Hedge Fund Activity: Q3 2018 in Review

529 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q3 2018, worth a combined $17.9B — up 12% from $16B a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new ABMD positions and 63 closed out — a net gain of 8 holders — while 202 added to existing stakes and 184 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $314M. The largest seller was Baillie Gifford & Co, cutting an estimated $513M.

  • 529 institutional investors held Abiomed Inc (ABMD) as of Q3 2018, up from 527 in Q2 2018.
  • Funds reported $17.9B of Abiomed Inc stock for Q3 2018, up 12% quarter-over-quarter.
  • 71 funds opened new Abiomed Inc positions in Q3 2018 and 63 closed out, a net change of +8 holders.
  • The largest Abiomed Inc buyer in Q3 2018 was AQR Capital Management, an estimated $314M added.
  • The largest Abiomed Inc seller in Q3 2018 was Baillie Gifford & Co, an estimated $513M sold.

Based on aggregated 13F filings for Q3 2018.